title: Editorial Commentary: Where to Place the New Treatments for Clostridium difficile Infection?
authors.affiliation: Department I of Internal Medicine and Center for Integrated Oncology CIO Köln/Bonn, University Hospital of Cologne German Centre for Infection Research, Partner Site Bonn-Cologne Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, and Clinical Trials Center Cologne, ZKS Köln, University of Cologne, Germany.
authors.forename: Oliver A
authors.initials: OA
authors.lastname: Cornely
authors.affiliation: Department I of Internal Medicine and Center for Integrated Oncology CIO Köln/Bonn, University Hospital of Cologne German Centre for Infection Research, Partner Site Bonn-Cologne.
authors.forename: Maria J G T
authors.initials: MJ
authors.lastname: Vehreschild
mesh_terms: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D016360:Clostridioides difficile; D003015:Clostridium Infections; D006801:Humans; D014640:Vancomycin
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D014640:Vancomycin
keywords: Clostridium difficile; bezlotoxumab; fidaxomicin; recurrence; treatment pathway